NexImmune Shares Jump On Immunotherapy Pact For Rare Cancers, Autoimmune Disorders

• Selexis SA and NexImmune Inc (NASDAQ: NEXI) have agreed to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients.

• Per the agreement, NexImmune will leverage Selexis' SUREtechnology Platform, a suite of cell line development technologies significantly reducing the time, effort, and costs associated with developing high-performance mammalian cell lines.

• Also Read: NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition.

• The Selexis-generated cell lines will be used to manufacture HLA IgG4 fusion proteins and T cell co-stimulatory monoclonal antibodies that will be incorporated into NexImmune's proprietary AIM injectable nanoparticle modality.

• These nanoparticles are designed to be an off-the-shelf injectable modality to engage a patient's T cells to identify and kill various diseased cells within the body.

• The agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papillomavirus-associated tumors, and additional human leukocyte antigens (HLAs).

• Price Action: NEXI shares are up 21.4% at $1.53 on the last check Thursday.

See more from Benzinga

• Mirati's Adagrasib Shows Promising Efficacy In KRAS Mutated Colorectal Cancer

• Top Financial Stories Thursday, September 08: Amazon Slows Down Hiring, Netflix Focuses On Cost Cutting, iPhone 14 Will Be Available In Russia And More…

• Tesla Motors (TSLA) – If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much Y

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.